The Basics on Maraviroc episode artwork

EPISODE · Aug 6, 2007 · 33 MIN

The Basics on Maraviroc

from TheBody.com: Podcast Central

It's been a year since the United States approved a new HIV medication, and four long years since we witnessed the birth of a whole new class of meds. But on Aug. 6, 2007, the U.S. Food and Drug Administration gave the green light to maraviroc, which will be known by the brand name Selzentry. Maraviroc is the first in a new class of HIV meds known as CCR5 inhibitors. Which HIV-positive people stand to benefit the most from maraviroc? How can you know if maraviroc's a good fit for you? To get the answers to these questions, we spoke with Dr. Joel Gallant, a professor of medicine and epidemiology at the Johns Hopkins University School of Medicine and one of the leading HIV specialists in the United States.

Episode metadata supplied by the publisher feed · Published Aug 6, 2007

Embed this episode

NOW PLAYING

The Basics on Maraviroc

0:00 33:14

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBody.com: Podcast Central?

This episode is 33 minutes long.

When was this TheBody.com: Podcast Central episode published?

This episode was published on August 6, 2007.

Can I download this TheBody.com: Podcast Central episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!